Details for New Drug Application (NDA): 219883
✉ Email this page to a colleague
NDA 219883 describes ROPIVACAINE HYDROCHLORIDE, which is a drug marketed by Amneal, Caplin, Eugia Pharma, Gland, Hikma, Hospira, Inforlife, Kindos, Mylan Labs Ltd, Navinta Llc, Neocubes Pharma, Rising, and Somerset Theraps Llc, and is included in sixteen NDAs. It is available from eighteen suppliers. Additional details are available on the ROPIVACAINE HYDROCHLORIDE profile page.
The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
Summary for 219883
| Tradename: | ROPIVACAINE HYDROCHLORIDE |
| Applicant: | Neocubes Pharma |
| Ingredient: | ropivacaine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 219883
| Physiological Effect | Local Anesthesia |
Suppliers and Packaging for NDA: 219883
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 219883 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-793 | 68462-793-55 | 25 VIAL in 1 CARTON (68462-793-55) / 20 mL in 1 VIAL (68462-793-20) |
| ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 219883 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-793 | 68462-793-74 | 10 VIAL in 1 CARTON (68462-793-74) / 20 mL in 1 VIAL (68462-793-20) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 40MG/20ML (2MG/ML) | ||||
| Approval Date: | Mar 21, 2025 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 150MG/30ML (5MG/ML) | ||||
| Approval Date: | Mar 21, 2025 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 200MG/20ML (10MG/ML) | ||||
| Approval Date: | Mar 21, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
